**A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis** This study is about testing a new drug called **buloxibutid** for treating *Idiopathic Pulmonary Fibrosis* (IPF), a lung disease that makes it hard to breathe. The medicine is taken by mouth and works by helping lung cells repair and grow better. The study will last **52 weeks** (about 1 year) and will compare buloxibutid to a placebo, which looks like the medicine but doesn't have any active drug. People who join the study will have their lung function checked using a test called **spirometry**, which measures how much air you can blow out of your lungs. Participants will take buloxibutid or a placebo twice a day for the whole year. About **360 people** will be part of the study, and they must be at least 40 years old and have been diagnosed with IPF in the last 7 years. - **Length**: 52 weeks treatment, with screening and follow-up. - **Visits**: Regular check-ups to monitor health and lung function. - **Treatment**: Participants may receive buloxibutid or a placebo. For more details, visit: [www.aspire-ipf.com](http://www.aspire-ipf.com/)